Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which diabetes drug is better for heart failure? new study compares tirzepatide and semaglutide

NCT ID NCT06914141

Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at over 28,000 people with type 2 diabetes and a type of heart failure called HFpEF. Researchers compared two drugs, tirzepatide and semaglutide, to see which one better reduces the risk of death or hospitalization for heart failure. The study used real-world data from insurance claims to mimic a clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide and semaglutide (drugs for diabetes and weight loss)
What this could lead to
If one drug proves clearly better, it could guide doctors to choose the most effective treatment for heart failure patients with diabetes.
What could go wrong
This is an observational study using existing data, not a controlled trial, so results may be influenced by unmeasured factors. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

28,118 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes individuals aged 40 years or older with heart failure with preserved ejection fraction.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligible cohort entry dates: Optum: Study period between May 13, 2022 to November 30, 2024. Marketscan: Study period between May 13, 2022 to December 31, 2023. Inclusion Criteria: * Heart failure * BMI \> 27.0 kg/m2 * History of type 2 diabetes mellitus * LVEF ≥ 45% * ≥ 18 years old, male or female sex Exclusion Criteria: * Prior treatment with any GLP-1-RA * History of type 1 diabetes mellitus * End-stage renal disease or chronic or intermittent haemodialysis or peritoneal dialysis * History of bariatric surgery * History of nursing home admission * Pregnant female or breastfeeding * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy * Treatment with continuous subcutaneous insulin infusion * Multiple endocrine neoplasia type 2 or medullary thyroid carcinoma * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) for less than 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Hfpef - heart failure with preserved ejection fraction

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.